← All trials
NCT03608163
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2018
- Primary completion
- Jul 31, 2020
- Completion date
- Jul 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yeshiva UniversityLead sponsor
- Yeshiva UniversityReponsible party - principal investigator
- Yeshiva UniversityOverall official - principal investigator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.